1. OGN shareholders may participate in class action regarding misleading statements. 2. Investors were misled about dividend policies post-Dermavant acquisition. 3. Stock price fell over 27% after dividend cuts were revealed. 4. The lawsuit highlights Organon's poor capital allocation management. 5. Shareholders must register by July 22, 2025, for legal participation.
The stock's sharp decline of over 27% indicates significant loss of investor confidence, reminiscent of other stocks facing legal challenges where price recovery took a long time. Historical similar situations show a trend of prolonged low valuations post-negative news.
Through potential legal actions and the impact on dividends, shareholders' trust is significantly eroded, which can lead to lasting consequences on stock performance.
Legal issues can take considerable time to resolve, potentially affecting OGN's stock price in the long run, similar to how companies like Valeant Pharmaceuticals took years to recover from legal backlash and regulatory scrutiny.
The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN).
Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=153669&from=4
October 31, 2024 to April 30, 2025
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Following this news, the price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day.
July 22, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=153669&from=4
Once you register as a shareholder who purchased shares of OGN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 22, 2025. There is no cost or obligation to you to participate in this case.
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
SOURCE: Gross Law Firm